key: cord-0793737-hb1synga
authors: Chua Vi Long, Keegan; Sayed, Abida; Karki, Priyanka; Acharya, Yogesh
title: Convalescent Blood Products in COVID-19: A Narrative Review
date: 2020-09-22
journal: Ther Adv Infect Dis
DOI: 10.1177/2049936120960646
sha: 81b794c51d6cd857d2fb4dd431d290997e9ea32b
doc_id: 793737
cord_uid: hb1synga

The coronavirus disease 2019 (COVID-19) pandemic has left the world in a state of desolation with overburdening public health systems in a short period. Finding possible preventative and therapeutic measures to counter severe respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has been the priority. A possible solution is convalescent blood products (CBP), primarily convalescent plasma (CP) and immunoglobulins, as an adjunctive therapy. CBP has been tried on the previous coronavirus epidemics with severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Therefore, we reviewed the clinical utility of CBP and available evidence in COVID-19. We found some of the current anecdotal studies demonstrate promising therapeutic potential, but many of these studies do not meet the academic rigours to substantiate its use with confidence. However, the compassionate use of CBP in critically ill COVID-19 patients can be an option while we await a definitive answer from ongoing randomised clinical trials.

articles were also involved. Studies carried out in the paediatric population were excluded. A separate assessment of the studies was executed for a secondary reference search on applicable supplementary research studies.

Convalescent blood products CBP consists of 5 :

1. convalescent whole blood or convalescent plasma or convalescent serum; 2. pooled human immunoglobulin for intravenous or intramuscular administration; 3. high-titre human immunoglobulin; and 4. polyclonal or monoclonal antibodies.

CBP is obtained from an individual who has developed humoral immunity and recovered from an infection. It is suppose to have high-titres of neutralising antibodies (NAb) used either for prophylactic passive inoculation or supportive treatment with the intention of reducing symptoms and mortality.

CBP has been used throughout history to confer artificially acquired passive immunity against various pathogens. The first use can be traced back between 1918 and 1920 during the Spanish Flu pandemic. [6] [7] [8] [9] [10] [11] A meta-analysis was conducted by Luke et al. regarding the effectiveness of CBP against Spanish influenza that involved eight studies and 1703 patients. 12 The study revealed significantly reduced mortality in CBP groups compared with untreated patients [16% versus 37% fatality; absolute risk difference 8% to 26%; pooled risk difference 21%, 95% confidence interval (CI): 15-27%] .

CBP continued to be used prophylactically against viral infections such as measles, varicella-zoster, and cytomegalovirus to variable effects due to the nature of its preparation. [13] [14] [15] Pooled human plasma tends to have inconsistent titres of NAbs. However, in 1944, Stokes et al. argued that the efficacy of CBP could be improved through more potent preparations and intravenous administration. 16 But, as definitive preventative tactics, such as vaccines, emerged, CBP became marginalised. Presently, CBP is used as a replacement therapy for congenital or acquired immunoglobulin production deficiencies.

During the 2002 SARS-CoV epidemic, there were no specific therapies/vaccines available for treatment. CBP therapeutic potential was first observed by Wong et al., 17 when a 57-year-old SARS-CoV infected woman received 200 ml CBP + 500 mg methylprednisolone and made an unremarkable recovery with no adverse drug reactions (ADRs). Similar recoveries were reported in three case series, including one pregnant female, and another woman, who subsequently became pregnant, without complications. [18] [19] [20] Separately, Soo et al. 21 found that patients (n = 19) receiving CBP + ribavirin-steroid had reduced admission lengths (p = 0.001) and mortality (p = 0.049) compared with patients (n = 21) receiving 1.5 g pulsed methylprednisolone. However, patients had a poor clinical response when CBP was given beyond 16 days post-symptom onset. Cheng et al. reported similar findings in 80 SARS-CoV infected patients with 279.3 ± 127.1 ml CBP (range:160-640 ml), with a greater 22-day discharge rate when CBP was given within 14 days of illness (58.3% versus 15.6%; p < 0.001). 22 A systematic review by Mair-Jenkins et al. analysed 32 studies regarding the efficacy of CBP against SARS and influenza and reported that mortality declined significantly in CBP patients [odds ratio (OR): 0.25; 95% CI: 0.14-0.45; I2 = 0%]. 23 They concluded that CBP is a safe therapeutic option with decreased mortality against SARS-CoV.

Similar to the 2002 SARS-CoV epidemic, no proven therapy was found during the 2012 MERS-CoV outbreak. By July 2014, 12 MAbs were identified to have prophylactic or therapeutic potential against MERS-CoV. [24] [25] [26] Subsequent rapid and affordable production of NAb LCA60, exhibiting MERS-CoV S protein interaction, demonstrated MAb/NAb as a viable option to combat emerging viral infections with low ADR risk. 27, 28 Of the 12 NAbs identified, m336 underwent further in vivo studies. Houser et al. reported that m336 significantly reduced viral titres (40-9000 fold) in rabbit lung tissue, 29 and these results were replicated in mouse models by Agrawal et al. 30 However, the therapeutic predictive value remains limited compared with non-human primate models. 31 34 it was challenging to obtain high CBP titre. They followed 11 MERS-CoV patients (five severe and six mild) for 12 months post-recovery, and found that severe patients tend to exhibit higher acute (0-6 months) and maintenance (6-12 months) PRNT90 titres, suggesting the possibility of obtaining effective high titre CBP only within the initial months of severe disease.

Overall, the quality of clinical evidence of CBP in SARS and MERS was low and lacked substantial support from RCTs for a definitive conclusion.

CBP has been used frequently against COVID-19 due to the existing therapeutic inertia. Here, we discuss the evidence concerning CBP in COVID-19 (summarised in Table 1 ). 35 35 Groups of Syrian hamsters were either given SARS-CoV-2 suspended in phosphate-buffered saline (PBS) (10 5 plaque-forming units/100 µl) or just 100 µl PBS. Compared with the control group, the SARS-CoV-2 challenged group had a weight loss of up to 11%, 1-6 days post inoculation (dpi). By 14 dpi, a high serum NAb titre >1:427 was achieved, weight was regained, but mild pulmonary congestion and infiltration were still detectable. Viral loads progressively declined in airway tissues between 2 and 7 dpi. The authors concluded that the prophylactic use of this hightitre CBP resulted in a significant decrease in viral lung load but no pathological changes in the lung.

By 27 March 2020, a case series by Shen et al. assessed the benefit of the CBP transfusion in five critically ill SARS-CoV-2 infected patients. 39 Each patient was infused with 400 ml CBP with a SARS-CoV-2 specific antibody binding titre >1:1000 and a neutralisation titre >1:40, between 10 and 22 days after admission. Following CBP therapy, the sequential organ failure assessment (SOFA) score decreased, and the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO 2 /FiO 2 ) increased within 12 days. Furthermore, 12 days post transfusion, the viral load became negative, NAb titres increased, and there was a resolution of acute respiratory distress syndrome (ARDS) in four patients. They concluded that administration of CBP with NAbs showed some potential as an effective treatment; however, their study was limited by small sample size and subordinate design. Subsequently, Zhang et al. 40 43 The first patient received CBP on day 12 of admission and was discharged by day 26. The second patient received CBP by day 27 and the viral nucleic acid turned negative after 4 days. The third patient suffered severe anaphylactic shock after receiving 30 ml of convalescent plasma from a 51-year-old pregnant woman. CBP treatment was immediately stopped, and the patient ultimately recovered and was discharged. This case highlights the importance of patient selection. Overall, the study showed that CBP use could lead to viral clearance as demonstrated by a negative viral nucleic acid test with a significant reduction in symptoms; however, careful patient selection should be conducted to prevent any adverse reactions.

On 28 April 2020, a case series by Duan et al. investigated the efficacy of CBP therapy in 10 severely ill COVID-19 patients. 44 In addition to antivirals and supportive care, patients were given 200 ml of CBP, NAb titre >1:640, with a median time of infusion at 16.5 days of symptom onset. The primary and secondary endpoints were the safety profile of CBP use and symptomatic improvement, respectively. Within 3 days post transfusion, oxyhaemoglobin increased, lymphocyte count increased (0.65 × 109/l versus 0.76 × 109/l) and CRP decreased (55.98 mg/l versus 18.13 mg/l). Within 7 days post transfusion, a variable radiological improvement was observed, and viral load was undetectable in seven patients.

No ADRs were observed. The authors concluded that CBP was well tolerated, and its use was associated with clinical improvement and neutralisation of viremia in COVID-19 patients.

On 29 April 2020, a case series by Zeng et al. assessed CBP efficacy in six critically ill COVID-19 patients. 45 The intervention group received 200-600 ml CBP (median volume: 300 ml) at a median infusion time of 21.5 days, following the first detection of viral shedding. The control and intervention group achieved 21.4% and 100% viral clearance before death (p = 0.005), with the intervention group all testing negative for SARS-CoV-2 RNA within 3 days of transfusion. Furthermore, the survival rate appeared to be longer in the intervention compared with the control group (p = 0.03); however, there were 5 deaths in the intervention and 14 in the control groups. Death in the intervention group was attributed to late CBP transfusion, and no immediate ADRs were reported. They concluded that CBP therapy has the potential to halt viral shedding and lengthen survival in patients without the end-stage disease if administered early in the course of the disease.

Rajendran et al. conducted a systematic review on 1 May 2020, with five eligible studies. 50 Based on the existing clinical evidence, they concluded that: (i) elevation in NAb titres with the disappearance of viral RNA was noted in nearly all patients following CBP administration, (ii) CBP had a beneficial effect on the clinical picture, and (iii) CBP might decrease mortality in critical COVID-19 patients. CBP was found to be safe and clinically effective, with a reduction in mortality. However, they recommended more extensive multicentre clinical trials to have conclusive evidence for efficacy. of severe to life-threatening COVID-19 cases receiving CBP (n = 39). 46 All 39 patients were given two CBP units (250 ml per unit), with a SARS-CoV-2 anti-spike antibody titre of >1:320, over 1-2 h at a median of 4 days from admission to transfusion. Patients were also receiving concomitant therapy that included azithromycin (n = 31), broad-spectrum antibiotics (n = 29), hydroxychloroquine (n = 36), non-specified investigational anti-virals (n = 1), therapeutic anticoagulation (n = 26), corticosteroids (n = 22), and interleukin-6 inhibitors (n = 3 A total of 52 patients had between 200 ml and 500 ml of CBP each; however, 9 patients received an additional 300 ml (n = 1), 400 ml (n = 4), 600 ml (n = 2), 900 ml (n = 1) and 2400 ml (n = 1) within a week, following non-response to the initial CBP dose and the presence of clinical deterioration. The CBP titres were not specified. In total, 50.8% (n = 31) recovered within the first week and 39.3% (n = 24) recovered between 8 and 29 days following CBP transfusion. There were no available recovery data in 9.8% (n = 6). Regarding prevalence of viral RNA post transfusion, 66.7% (n = 24) and 30.6% (n = 11) were negative within the first week and 8-29 days, respectively. There was no significant difference in recovery rate after CBP therapy between gender, or the presence of underlying comorbidities, receiving CBP within 3 weeks or beyond following symptom onset. It was concluded that CBP therapy was safe and had a positive recovery response in about half of patients, particularly those younger than 60 years. However, a definitive conclusion regarding the effectiveness of CBP was difficult due to the relatively small number of patients and multiple concomitant treatments. 37 Post-infection sera were collected from hamsters infected with either high (10 5.6 PFU) or low (10 3 PFU) dosages of the SARS-CoV-2 UT-NCGM02 strain. Infected sera were given either 1 or 2 days post-infection while two control groups received uninfected hamster sera. The hamsters receiving CBP 1 day postinfection were found to have significantly lower viral titres in the nasal turbinates (p < 0.05) and lungs (p < 0.01) compared with control groups. Similarly, statistically insignificant lower viral titres were reported in hamsters receiving CBP 2 days post infection compared with control (5.9 ± 1.8 log10 PFU ± SD/g versus 7.8 ± 0.1 PFU ± SD/g). Hamsters with SARS-CoV-2 infection had evoked NAbs resulting in the protection of hamsters from further infection, and viral replication was prevented more effectively in lungs than in nasal turbinates. The study concluded that anti-SARS-CoV-2 polyclonal hyperimmune globulin from CBP derived from COVID-19 patients and MAbs against SARS-CoV-2 could reduce viral loads in patients.

As stated by Kalil et al., we must be cautious in a fallacy on unproven drug efficacy. 53 It is not necessarily true that any death must be due to disease, and, likewise, any survival must be due journals.sagepub.com/home/tai 15 to therapeutic intervention. Past studies relating to SARS and MERS lend no substantial credibility to the efficacy of CBP. They were inconsistent, with vague methodology, and had several limitations like small sample sizes, lacked of large-scale trials, blinding, randomisation and control groups, and tested many concomitant treatments. 54 Although we did not perform quality assessment, we found the majority of existing CBP clinical studies in COVID-19 to be mainly case-based, lacking randomisation and standardisation, with sub-standard quality of methodology, and thus having low applicability and generalisability. Selection bias may also significantly skew the results, contributing to an already difficult interpretation. 48, 55 Therefore, additional RCTs must be conducted to provide conclusive evidence.

CBP has the capacity for adverse reactions, similar to regular plasma transfusions. 56 Mild allergy is common, but serious adverse events like transfusion-associated circulatory overload (TACO) are possible, with an elevated risk in the elderly with acute lung damage under mechanical ventilation and those with viral myocarditis. 57 Furthermore, the risk of complement and coagulation pathways activation with CBP is also a concern, due mainly to a potential for complement-dependent antibody enhancement due to COVID-19. 58 Also, the potential of blood-borne infection cannot be ignored. The Pathogen Reduction Technology (PRT) system, using ultraviolet light and riboflavin, have shown an effective reduction of the SARS-CoV-2 in plasma and blood products without decreasing the quality of the blood products, which could be utilised to reduce the risk of transfusion-related viral transmission. 59 However, CBP is thoroughly tested before its use and specially screened for hepatitis B/C, human immunodeficiency virus (HIV), and other infections. Notably, SARS-CoV-2 is not a blood-borne pathogen; therefore, CBP is safe and theoretically the risk of SARS-CoV-2 transmission from donor CBP is not possible. 60

We found some potential limitations of the clinical utility of CBP as a viable therapy in COVID-19, notably, (i) lack of robust clinical evidence, (ii) sufficient production of CBP, and (iii) production of CBP with consistent standard and safety. However, given the antiviral history of CBP and the absence of a definitive therapy against COVID-19, certain authorities such as the United States (US) Food and Drug Administration (FDA) have urgently authorised the therapeutic use of CBP, albeit within the framework of the strict guidelines suggested by scientific entities. 58, 61, 62 This is to standardise treatment, minimise any unforeseen ADRs and allow for subsequent academic investigations.

As of 11 June 2020, 63 interventional trials investigating the efficacy of CBP against COVID-19 were listed on the 'ClinicalTrials.gov' (https:// clinicaltrials.gov/) ( Table 2) . Therefore, it would be interesting to wait for their outcomes to have a definitive conclusion.

Finally, we can say that CBP, either as a monotherapy or in combination with other antiviral drugs, could be an option. Although the optimal antibody titre is unknown, the FDA recommends titer of 1:160, which could be as low as 1:80 if higher titres are unavailable. 63 Similarly, while there are uncertainties regarding the timing of CBP delivery during the course of the disease, studies have shown greater clinical recovery and discharge rate when given within 14 days of illness and poor clinical response after 16 days postsymptoms. 19, 20 Therefore, the CBP infusion should be of high titre, serologically screened for blood-borne pathogens, administered within 14 days of symptom onset, and the patient should be monitored during and after infusion to observe for any potential ADRs.

The clinical evidence for CBP against COVID-19 is insufficient. Some current anecdotal studies demonstrate promising therapeutic potential, but these studies do not meet the academic rigours to substantiate its use with confidence. However, the compassionate use of CBP in critically ill COVID-19 patients can be an option while we are awaiting a definitive answer from ongoing RCTs.

1. Currently, clinical evidence on CBP is limited to observational studies and further RCTs or large prospective studies are necessary to provide conclusive evidence.

World Health Organisation (WHO)

WHO Coronavirus Disease

Dexamethasone in hospitalized patients with Covid-19 -preliminary report

ACTT-1 study group members. Remdesivir for the treatment of Covid-19 -preliminary report

A Novel Coronavirus from patients with pneumonia in China

Convalescent plasma: new evidence for an old therapeutic tool?

Early use of convalescent serum in influenza

Treatment of influenza-pneumonia by use of convalescent human serum

Treatment of influenza pneumonia with serum from convalescents

Influenza pneumonia treated by blood transfusion

Report of influenza treated with serum from recovered cases

Injection of whole blood in influenza

Metaanalysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Convalescent whole blood, plasma and serum in the prophylaxis of measles

Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases

Passive immunity in prevention and treatment of infectious diseases

Chemical, clinical, and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal Human Serum Gamma Globulin (Human Immune Serum Globulin) in the prophylaxis and treatment of measles

Treatment of severe acute respiratory syndrome with convalescent plasma

Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area

Letter to the editor

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Use of convalescent plasma therapy in SARS patients in Hong Kong

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral Etiology: a systematic review and exploratory meta-analysis

Potent veutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

Exceptionally potent neutralization of middle East respiratory syndrome coronavirus by human monoclonal antibodies

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS Coronavirus

Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with Middle East Respiratory Syndrome

Prophylaxis with a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection

Passive transfer of a Germline-like neutralising human monoclonal antibody protects transgenic mice against lethal Middle East Respiratory Syndrome Coronavirus infection

Genomic responses in mouse models poorly mimic human inflammatory diseases

Efficacy of antibody-based therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in common marmosets

Challenges of convalescent plasma infusion therapy in Middle East Respiratory Coronavirus infection: a single centre experience

MERS-CoV antibody responses 1 year after symptom onset, South Korean

Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. Epub ahead of print 15

Syrian hamster as an animal model for the study of human influenza virus infection

High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19

Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Convalescent plasma to treat COVID-19: Chinese strategy and experiences

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019

Convalescent plasma treatment of severe COVID-19: a matched control study

Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19: a randomized clinical trial

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Convalescent plasma transfusion for the treatment of COVID-19: systematic review

A systematic review of convalescent plasma treatment for COVID19. medRxiv. Epub ahead of print 5

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Treating COVID-19 -off-label drug use, compassionate use, and randomized clinical trials during pandemics

Potential rapid diagnostics, vaccine and therapeutics for 2019 novel Coronavirus (2019-nCoV): a systematic review

A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals

Convalescent plasma and COVID-19 JAMA. Epub ahead of print 12

COVID-19 convalescent plasma: now is the time for better science

Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. Epub ahead of print 2

Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet lightbased photochemical treatment. Vox Sang. Epub ahead of print

Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang. Epub ahead of print 2

Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

Potential interventions for novel coronavirus in China: a systematic review

Investigational COVID-19 convalescent plasma -emergency INDs

Author contributions KCVL, AS and YA made substantial contributions to the conception and study design, data acquisition and interpretation. All authors were involved in drafting the manuscript as well as the revision process. All authors have approved the final version of the manuscript.

The authors declare that there is no conflict of interest.

The authors received no financial support for the research, authorship, and/or publication of this article.

Keegan Chua Vi Long https://orcid.org/0000-0001-5946-0616 Yogesh Acharya https://orcid.org/0000-0003-1829-5911